Mark E Delaney Net Worth

The estimated Net Worth of Mark E Delaney is at least 831 千$ dollars as of 24 July 2024. Mark Delaney owns over 420 units of Quest Diagnostics stock worth over 770,718$ and over the last 2 years Mark sold DGX stock worth over 60,094$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mark Delaney DGX stock SEC Form 4 insiders trading

Mark has made over 1 trades of the Quest Diagnostics stock since 2024, according to the Form 4 filled with the SEC. Most recently Mark sold 420 units of DGX stock worth 60,094$ on 24 July 2024.

The largest trade Mark's ever made was selling 420 units of Quest Diagnostics stock on 24 July 2024 worth over 60,094$. On average, Mark trades about 70 units every 0 days since 2023. As of 24 July 2024 Mark still owns at least 5,019 units of Quest Diagnostics stock.

You can see the complete history of Mark Delaney stock trades at the bottom of the page.

What's Mark Delaney's mailing address?

Mark's mailing address filed with the SEC is 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS, NJ, 07094.

Insiders trading at Quest Diagnostics

Over the last 21 years, insiders at Quest Diagnostics have traded over 67,426,608$ worth of Quest Diagnostics stock and bought 34,000 units worth 1,910,090$ . The most active insiders traders include Plc Gsk、James F Iii Flaherty、Jeffrey M Leiden. On average, Quest Diagnostics executives and independent directors trade stock every 19 days with the average trade being worth of 3,750,703$. The most recent stock trade was executed by Michael E Prevoznik on 29 August 2024, trading 32,551 units of DGX stock currently worth 3,118,386$.

What does Quest Diagnostics do?

quest diagnostics (nyse: dgx) empowers people to take action to improve health outcomes. derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. quest annually serves one in three adult americans and half the physicians and hospitals in the united states, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. the company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (ap) services, & interpretive consultation through its medical & scientific staff of about 900 m.d.s & ph.d.s. the company reported 2014 revenues of $7.4 billion. quest diagnostics offers the most extensive clinical testing network in the u.s., with laborator

Complete history of Mark Delaney stock trades at Quest Diagnostics

Quest Diagnostics executives and stock owners

Quest Diagnostics executives and other stock owners filed with the SEC include:

• Stephen Rusckowski,
  Chairman of the Board, President, Chief Executive Officer
• Manuel Mendez,
  Executive Officer
• Stephen H. Rusckowski,
  Chairman, Pres & CEO
• Mark Guinan,
  Chief Financial Officer, Executive Vice President
• James Davis,
  Executive Vice President, General Diagnostics
• Carrie Manner,
  Senior Vice President - Advanced Diagnostics
• Catherine Doherty,
  Senior Vice President, Group Executive - Clinical Franchise Solutions and Marketing
• Michael Prevoznik,
  Senior Vice President, General Counsel
• James E. Davis,
  Exec. VP of Gen. Diagnostics
• Carrie Eglinton Manner,
  Sr. VP of Advanced Diagnostics
• Daniel Stanzione,
  Lead Independent Director
• Gary Pfeiffer,
  Independent Director
• Denise Morrison,
  Independent Director
• Gail Wilensky,
  Independent Director
• Timothy Main,
  Independent Director
• Timothy Ring,
  Independent Director
• Vicky Gregg,
  Independent Director
• Helen Torley,
  Independent Director
• Wright Lassiter,
  Independent Director
• Michael E. Prevoznik,
  Sr. VP & Gen. Counsel
• Mark J. Guinan,
  Exec. VP & CFO
• Gary D. Samuels,
  VP of Corp. Communications
• Timothy Sharpe,
  VP of Compliance
• Shawn C. Bevec,
  VP of Investor Relation
• Gabrielle Wolfson,
  Sr. VP and Chief Information & Digital Officer
• Michael J. Deppe,
  VP, Corp. Controller & Chief Accounting Officer
• Robert B Carter,
  Director
• Jeffrey M Leiden,
  Director
• Jenne K Britell,
  Director
• Robert A Klug,
  VP, Corporate Controller
• Everett Cunningham,
  SVP, Commercial
• John B Ziegler,
  Director
• Jon R Cohen,
  SVP and Chief Medical Officer
• William F Buehler,
  Director
• John B. Haydon,
  SVP, Operations
• Kathy Ordonez,
  SVP, Discovery & Development
• Robert Hagemann,
  Corp VP & Chief Fin Officer
• Surya N Mohapatra,
  President & COO
• Joan Elizabeth Miller,
  Sr VP -Pathology& HospServices
• John C Md Baldwin,
  Director
• Wayne R. Simmons,
  Vice President, Operations
• Rosanne Haggerty,
  Director
• Plc Gsk,
  10% owner
• Thomas W Ii Grant,
  Executive Officers
• William R Grant,
  Director
• Thomas F Bongiorno,
  Vice President and Controller
• James F Iii Flaherty,
  Director
• David M Zewe,
  Sr. VP -Diagnostic Testg Ops
• Robert E Peters,
  Vice President, Sales & Mktg.
• Kenneth W/Nj Freeman,
  Chairman, Chief Exec Officer
• Mary A Cirillo,
  Director
• Kenneth D Brody,
  Director
• Gerald C Marrone,
  Sr. VP, Administration
• Luis Diaz,
  Director
• Tracey Doi,
  Director
• Michael J Deppe,
  SVP, Corp. Controller & CAO
• Sam Samad,
  Executive Vice President & CFO
• Patrick Plewman,
  SVP for Diagnostic Services
• Karthik Kuppusamy,
  SVP, Clinical Solutions
• J. E. Davis,
  CEO and President
• Mark E Delaney,
  SVP & Chief Commercial Officer
• Mark A Gardner,
  SVP of Molecular Gen & Oncol